Literature DB >> 3706000

The Skaraborg hypertension project. II. Feasibility of a medical care program for hypertension.

L Råstam, G Berglund, S O Isacsson, L Rydén.   

Abstract

The feasibility of a nurse-based care program for hypertension has been evaluated. The program was established in one half of the County of Skaraborg, the other half being selected as control area. Record forms from the diagnostic work-up and annual check-ups of all 3240 patients registered during five years were reviewed. Compliance with diagnostic procedures and treatment was excellent. At the end of the five-year trial period, 7% of the population studied (40-69 years old) were registered at special outpatient hypertension clinics. Random samples were drawn of patients treated at these clinics and patients taken care of in the control area. These patients were interviewed concerning their general opinion about the care, their opinion about nurses as the main deliverers of care, the continuity of care and needs for information. The comparisons favoured care at the hypertension clinics. It is concluded that the program was feasible and preferred to conventional care by the consumers.

Entities:  

Mesh:

Year:  1986        PMID: 3706000

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  3 in total

1.  Control of blood pressure and risk of first acute myocardial infarction: Skaraborg hypertension project.

Authors:  U Lindblad; L Råstam; L Rydén; J Ranstam; S O Isacsson; G Berglund
Journal:  BMJ       Date:  1994-03-12

2.  Detecting hypertension: screening versus case finding in Norway.

Authors:  J Holmen; L Forsén; P F Hjort; K Midthjell; H T Waaler; A Bjørndal
Journal:  BMJ       Date:  1991-01-26

3.  The Asp298 allele of endothelial nitric oxide synthase is a risk factor for myocardial infarction among patients with type 2 diabetes mellitus.

Authors:  Jacob Odeberg; Charlotte A Larsson; Lennart Råstam; Ulf Lindblad
Journal:  BMC Cardiovasc Disord       Date:  2008-12-10       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.